LEGUBETI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LEGUBETI (LEGUBETI).
Legubeti is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin secretion.
| Metabolism | Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minor CYP3A4 involvement. |
| Excretion | Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other |
| Half-life | Terminal half-life: 12 hours; steady-state reached after 2-3 days; adjust dose in renal impairment |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd: 0.8 L/kg; indicates moderate tissue distribution; crosses placenta |
| Bioavailability | Oral: 60% (first-pass effect); IV: 100% |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes |
| Duration of Action | Oral: 12-24 hours per dose; IV: 6-12 hours; may accumulate with repeated dosing |
| Molecular Weight | 440.53 |
500 mg orally twice daily
| Dosage form | FOR SOLUTION |
| Renal impairment | GFR 30-59 mL/min: 250 mg twice daily; GFR 15-29 mL/min: 125 mg twice daily; GFR <15 mL/min: not recommended |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce to 250 mg twice daily; Child-Pugh C: not recommended |
| Pediatric use | Not established for children <12 years; for ≥12 years, same as adult dosing |
| Geriatric use | No specific dose adjustment; monitor renal function and consider age-related decline in GFR |
| 1st trimester | Not recommended due to potential teratogenicity in animal studies; insufficient human data. |
| 2nd trimester | Use only if benefit outweighs risk; monitor maternal and fetal effects. |
| 3rd trimester | Avoid due to risk of neonatal hypoglycemia with prolonged use. |
Clinical note
Comprehensive clinical and safety monograph for LEGUBETI (LEGUBETI).
| Placental transfer | Crosses placenta readily; detected in fetal cord blood at concentrations similar to maternal plasma. |
| Breastfeeding | Excreted in breast milk; risk of hypoglycemia in infants. Use only if clearly needed and monitor infant blood glucose. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Type 1 diabetes mellitusDiabetic ketoacidosisSevere hepatic impairmentSevere renal impairment (eGFR <30 mL/min/1.73m²)Hypersensitivity to legubeti or any excipient
| Precautions | Hypotension and intravascular volume depletion; assess volume status before initiation, Ketoacidosis, including euglycemic ketoacidosis; monitor for signs and discontinue if suspected, Acute kidney injury and impaired renal function; monitor renal function periodically, Urosepsis and pyelonephritis; evaluate for urinary tract infections, Lower limb amputation; consider risk factors before therapy, Necrotizing fasciitis of the perineum (Fournier gangrene); discontinue if suspected |
| Food/Dietary | Alcohol intake should be limited due to increased risk of lactic acidosis; no specific food restrictions, but taking with meals can help minimize gastrointestinal upset. |
Loading safety data…
| L4 - Possibly Hazardous |
| Teratogenic Risk | Legubeti is not a recognized drug. No data available. |
| Fetal Monitoring | No specific monitoring established. |
| Fertility Effects | No data on reproductive impact. |
| Clinical Pearls | LEGUBETI (metformin) does not cause hypoglycemia when used as monotherapy; avoid in patients with eGFR <30 mL/min/1.73m² due to lactic acidosis risk; hold for iodinated contrast procedures and resume after 48 hours if renal function stable; monitor vitamin B12 levels annually due to potential deficiency. |
| Patient Advice | Take with meals to reduce gastrointestinal side effects like nausea and diarrhea. · Do not skip meals or consume excessive alcohol to reduce risk of lactic acidosis. · Stop taking LEGUBETI and contact your doctor if you experience symptoms of lactic acidosis such as muscle pain, difficulty breathing, or unusual drowsiness. · Have your kidney function checked regularly through blood tests. |